Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
- Conditions
- Metastatic Breast CarcinomaRecurrent Breast CarcinomaBreast Carcinoma
- Interventions
- Other: Non-Interventional Study
- Registration Number
- NCT06217874
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This study is being done to create a resource of samples and information that can be used to improve our understanding of the development, progression and treatment of recurrent or metastatic breast cancer or male breast cancer.
- Detailed Description
PRIMARY OBJECTIVE:
I. To collect blood samples and fresh tissue from biopsies of metastatic lesions from Mayo Clinic patients with metastatic breast cancer.
OUTLINE: This is an observational study.
Patients undergo blood sample collection, tumor biopsy and have their medical records reviewed on study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 5000
- Female participants must have histologically or cytologically confirmed invasive breast cancer.
- Male participants must have biopsy proven breast cancer.
- Age must be >= 18 years, and all must be able to understand and willing to sign an informed consent document.
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent; a history of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine).
- Any other condition, which in the opinion of the patient's treating oncologist, or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Observational Non-Interventional Study Patients undergo blood sample collection, tumor biopsy (during clinically scheduled biopsy), and have their medical records reviewed on study.
- Primary Outcome Measures
Name Time Method Response to targeted therapies Baseline Response to targeted therapies will be evaluated in organoid or mouse xenograft models derived from tumor biospecimens obtained from participants.
Change in tumor cells Baseline Changes in tumor cells will be evaluated following metastasis to other organs and after various treatments.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States